Acceleron Pharma, Inc.

( )
XLRN PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Biotechnology
MRNAModerna, Inc. 0.37%283.400.0%$3951.53m
BNTXBioNTech SE -3.55%291.940.0%$1261.44m
NVAXNovavax, Inc. -0.60%181.7578.2%$864.57m
AMGNAmgen, Inc. 1.05%213.531.4%$651.58m
LGVNLongeveron Inc. 11.85%21.900.0%$515.31m
GILDGilead Sciences, Inc. 0.09%69.711.0%$515.13m
VRTXVertex Pharmaceuticals, Inc. 0.68%206.611.9%$454.10m
REGNRegeneron Pharmaceuticals, Inc. 2.98%654.042.7%$419.38m
ILMNIllumina, Inc. 1.77%375.983.3%$351.77m
SNSSSunesis Pharmaceuticals, Inc. 1.16%4.360.7%$304.78m
BIIBBiogen, Inc. 3.48%234.721.8%$297.97m
SGENSeagen Inc. 2.12%149.555.8%$157.99m
EXASEXACT Sciences Corp. 3.48%86.2618.0%$150.95m
INCYIncyte Corp. 0.90%67.332.4%$147.13m
BMRNBioMarin Pharmaceutical, Inc. 2.62%88.384.2%$138.75m

Company Profile

Acceleron Pharma, Inc. operates as a biopharmaceutical company. The company engages in developing, manufacturing, and commercializing novel biotherapeutics that modulate the growth of bone, muscle, fat, and the vasculature to treat musculoskeletal, metabolic, and cancer-related diseases. Its products include ACE-011 Program, a novel bone forming agent that helps to treat cancer-related bone loss; ACE-031 Program that helps to treat diseases involving the loss of muscle mass, strength, and function in diseases, including muscular dystrophy, amyotrophic lateral sclerosis, and cancer-related muscle loss; and ACE-041, a protein therapeutic that binds a member of the growth and differentiation factor family necessary for angiogenesis. It develops therapies based on growth and differentiation factors that regulate the cellular proliferation, differentiation, and survival of a range of tissue types. The company offers treatments for cancer-related bone loss, cancer-related muscle loss, neuromuscular diseases, and metabolic disorders. Acceleron Pharma, Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.